SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 1-Year High – Should You Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $7.88 and last traded at $7.67, with a volume of 408022 shares trading hands. The stock had previously closed at $7.71.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, HC Wainwright increased their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Price Performance

The firm has a 50-day simple moving average of $5.79 and a 200-day simple moving average of $5.19. The firm has a market capitalization of $635.05 million, a PE ratio of -6.58 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. As a group, equities analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Insider Activity

In other SOPHiA GENETICS news, insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00. Following the sale, the insider directly owned 223,387 shares of the company’s stock, valued at $1,264,370.42. This trade represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.60, for a total value of $38,000.00. Following the sale, the chief technology officer directly owned 182,171 shares in the company, valued at $1,384,499.60. This trade represents a 2.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 309,592 shares of company stock valued at $1,884,635. 4.88% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC boosted its holdings in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Principal Financial Group Inc. lifted its position in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the last quarter. Archon Capital Management LLC lifted its holdings in shares of SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after acquiring an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the 1st quarter valued at about $2,157,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.